title: GnRH mediates estrous behavior induced by ring A reduced progestins and vaginocervical stimulation.
abstract: The present study was designed to assess the participation of gonadotropin-releasing hormone (GnRH) in the display of estrous behavior induced by application of vaginal-cervical stimulation (VCS) and by the intracerebroventricular (icv) administration of progesterone and its ring A-reduced metabolites to ovariectomized (ovx), estradiol benzoate (E2B) primed rats. Icv injection of Antide, a GnRH-1 receptor antagonist, significantly depressed lordosis behavior in ovx, E2B-primed rats treated with icv GnRH. Application of VCS to ovx, E2B-primed rats facilitated both lordosis and proceptivity. These behavioral responses were significantly depressed by the icv administration of Antide. Similarly, icv Antide blocked the stimulatory effect on both lordosis and proceptive behaviors elicited by progesterone and its ring A-reduced metabolites: 5alpha-pregnandione (5alpha-DHP), 5alpha-pregnan-3alpha-ol-20-one (5alpha,3alpha-Pgl) and 5beta-pregnan-3beta-hydroxy-20-one (5beta,3beta-Pgl) in ovx, E2B-primed rats. By contrast, icv injection of Antide failed to interfere with the facilitatory effect of the synthetic progestin megestrol acetate on lordosis and proceptive behaviors. This progestin is not reduced in ring A. The results suggest that GnRH release is an important process in the chain of events leading to the display of estrous behavior in response to progesterone, its ring A-reduced metabolites, and VCS in female rats.
authors: Centro de Investigación en Reproducción Animal, CINVESTAV Universidad Autónoma de Tlaxcala. Apdo. 62, Tlaxcala, c.p. 90000, Mexico.
authors: Porfirio
authors: P
authors: Gómora-Arrati
authors: Carlos
authors: C
authors: Beyer
authors: Francisco Javier
authors: FJ
authors: Lima-Hernández
authors: Maria Elena
authors: ME
authors: Gracia
authors: Anne M
authors: AM
authors: Etgen
authors: Oscar
authors: O
authors: González-Flores
mesh_terms: D000818:Animals; D002584:Cervix Uteri / Q000502:physiology*; D004958:Estradiol / Q000494:pharmacology; D030762:Estrous Cycle / Q000187:drug effects*; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000037:antagonists & inhibitors* / Q000378:metabolism / Q000494:pharmacology*; D006727:Hormone Antagonists / Q000494:pharmacology*; D007276:Injections, Intraventricular; D019290:Megestrol Acetate / Q000037:antagonists & inhibitors / Q000494:pharmacology; D009842:Oligopeptides / Q000494:pharmacology*; D010052:Ovariectomy; D010812:Physical Stimulation; D011187:Posture; D011372:Progestins / Q000737:chemistry / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012726:Sexual Behavior, Animal / Q000187:drug effects*; D014621:Vagina / Q000502:physiology*
chemical_list: D006727:Hormone Antagonists; D009842:Oligopeptides; D011372:Progestins; D007987:Gonadotropin-Releasing Hormone; D004958:Estradiol; C057022:iturelix; D019290:Megestrol Acetate